Radiopharm Theranostics (ASX:RAD) has announced a positive new publication regarding its RAD301 (αVβ6-Integrin) platform.
The company is developing a platform of radiopharmaceutical products for both diagnostic and therapeutic uses.
Cancer Biotherapy and Radiopharmaceuticals published the abstract - ‘Validation of In-House Kit-Like Synthesis of 68Ga-Trivehexin and Its Biodistribution for Targeting the Integrin αVβ6 Expressing Tumors’ - which evaluated the uptake of Trivehexin in 20 patients with αVβ6 expressing head and deck and pancreatic cancer.
The company said the results included intense radiotracer uptake in the tumour without uptake in healthy tissues. It was also observed that PET/CT imaging at 60 minutes post injection was the optimal time for imaging the tumours with 68Ga-Trivehexin.
The abstract concluded that 68Ga-Trivehexin is an extremely promising agent for non-invasive molecular imaging of Integrin αVβ6 expressing tumours.
Radiopharm Theranostics Managing Director and CEO Riccardo Canevari said, “This is further pleasing evidence of the impact of this piece of our pipeline, which we are eager to continue development of.
“We’d like to acknowledge Parul Thakral, Subha Shankar Das, Shweta Dhiman, Divya Manda, C.B. Virupakshappa, Dharmender Malik, and Ishita Sen at Department of Nuclear Medicine, Fortis Memorial Research Institute; and Dr Jakub Simecek of TRIMT, GmbH, Radeberg, Germany, who provided the investigators with the peptide (Trivehexin) and helped with labelling technique. These individuals and organisations were key in making this work possible.”